OCULOcular Therapeutix, Inc.
$7.53-38% 1Y
$7.53
$6.8852 weeks$16.11
The financials
Ocular Therapeutix, Inc. by the numbers
Ocular Therapeutix, Inc. (OCUL) reported revenue of $13M in Q2 2026 (quarter ended Jun 30, 2026), up 0.1% from the same quarter a year earlier. That came with a gross margin of 85% and net loss of $79M. For the full year FY2025, revenue was $52M (−18% year on year) and net income −$266M. Its largest product in Q3 2024 (quarter ended Sep 30, 2024) was Collaboration at $78K, 50.0% of the disclosed total, just ahead of Otx Tic Product at 50.0%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $13M | $13M | +0.1% |
| Gross profit | $11M | $12M | −0.4% |
| Operating income | −$82M | −$68M | n/a |
| Net income | −$79M | −$68M | n/a |
| Diluted EPS | −$0.35 | −$0.39 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $78K | 50% |
| Otx Tic Product | $78K | 50% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $0.00
Segment Latestyear on year
On our screens:Most shorted stocks